Insights from pediatric neurologist Carsten Bönnemann

posted on July 1, 2013 - 9:23am
Update (March 24, 2015): A phase 1 trial of omigapil in children and adolescents 5-16 years old who have merosin-deficient congenital muscular dystrophy and meet other study criteria is open in Bethesda, Md. See Assessment of Safety and Tolerability of Omigapil (CALLISTO), or enter NCT01805024 in the search box at ClinicalTrials.gov.


posted on March 31, 2010 - 2:56pm
QUEST Vol. 17, No. 2
Featured in this issue: Disappointing results from ataluren trial leads to further analysis * First U.S. site for idebenone in DMD trial opens * Utrophin-boosting drug begins safety tests * Participants sought for trials in DMD, CMD, myotonic distrophy and periodic paralysis Study of PGD seeks couples who said 'no'
posted on May 1, 2007 - 4:04pm
QUEST Vol. 14, No. 3
New muscle-generating stem cells isolated from human tissue Researchers at several U.S. and Italian institutions say they’ve isolated from human skeletal muscle a new type of stem cell that they believe could be “ideal” for the treatment of muscular dystrophy. MDA-supported Giulio Cossu at the San Raffaele Scientific Institute in Milan, Italy, and Paolo Bianco of the San Raffaele Biomedical...